SlideShare a Scribd company logo
1 of 19
Download to read offline
Patterns of Care in  Medical Oncology Adjuvant Trastuzumab
Patients with HER2-positive, node-negative breast tumors  1-2 cm  should generally receive adjuvant trastuzumab/chemotherapy as part of their treatment. 5% 0% Disagree 12% 24% In between 83% 76% Agree ER-positive ER-negative 0% 2% 98% 3% 8% 89% Disagree In between Agree Clinical investigators Practicing oncologists
Patients with HER2-positive, node-negative breast tumors  smaller than 1 cm  should generally receive adjuvant trastuzumab/chemotherapy as  part of their treatment. 33% 35% Disagree 40% 47% In between 27% 18% Agree ER-positive ER-negative 14% 49% 37% 15% 37% 48% Disagree In between Agree Clinical investigators Practicing oncologists
When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy  regimen do you generally use? 2007 2006 12% 2% Other 0% 2% AC  paclitaxel q3wk Clinical investigators (CI) 0% 20% 22% 46% 4% AC  docetaxel 2% 25% 65% Docetaxel/carboplatin Dose-dense AC  paclitaxel q2wk AC  paclitaxel qwk
When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy  regimen do you generally use? 2006 PO n = 143 2007 2006 9% 2% Other 13% 2% AC  paclitaxel q3wk Practicing oncologists (PO) 9% 8% 27% 34% 17% AC  docetaxel 4% 31% 44% Docetaxel/carboplatin Dose-dense AC  paclitaxel q2wk AC  paclitaxel qwk
Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are unable to receive chemotherapy. 2007 2006 Clinical investigators (CI) 30% 35% 35% 38% 24% 38% Disagree In between Agree
Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are  unable to receive chemotherapy. 2007 2006 Practicing oncologists (PO) 17% 33% 50% 27% 36% 37% Disagree In between Agree
Approximately what percent of your patients on adjuvant trastuzumab fail to complete one year of trastuzumab therapy? 10% 13% Mean Clinical investigators Practicing oncologists
Have you used TCH as nonprotocol adjuvant therapy for patients with HER2-positive tumors? 75% 44% Percent answering yes Clinical investigators Practicing oncologists
For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/taxane/trastuzumab regimen? * CI n = 49, PO n = 147 1% 0% My preferred regimen is significantly more efficacious Efficacy* 33% 65% 2% 0% 30% My preferred regimen is somewhat more efficacious 54% 13% 2% Both are similar in efficacy TCH is somewhat more efficacious TCH is significantly more efficacious Clinical investigators Practicing oncologists
For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/taxane/trastuzumab regimen? †   CI n = 49, PO n = 149 0% 2% My preferred regimen has significantly better safety and tolerability Safety and tolerability † 8% 37% 33% 20% 7% My preferred regimen has somewhat better safety and tolerability 28% 53% 12% Both are similar in safety and tolerability TCH has somewhat better safety and tolerability TCH has significantly better safety and tolerability Clinical investigators Practicing oncologists
How would you feel in general about recommending participation in a randomized trial of TCH alone or with bevacizumab in women with HER2-positive breast cancer? 8% 6% I would not recommend participation 45% 41% Some concerns — I would enter patients selectively 53% 47% No concerns — I would enter patients Clinical investigators Practicing oncologists
Are you aware of the new data from the BCIRG 006 study comparing  AC    T to AC    TH and to TCH in the adjuvant treatment of HER2-positive, early breast cancer presented at the 2006 San Antonio Breast Cancer Symposium? AC   TH = doxorubicin/cyclophosphamide   docetaxel/trastuzumab;  TCH = docetaxel/carboplatin/trastuzumab Clinical investigators Practicing oncologists 100% 68% Percent answering yes
If yes, please respond to the following statements about the BCIRG 006 study: THC and AC    TH had roughly equivalent efficacy, and each was superior to AC    T 4% 0% Disagree 11% 10% In between 90% 85% Agree Clinical investigators Practicing oncologists
If yes, please respond to the following statements about the BCIRG 006 study: TCH had lower cardiovascular toxicity compared to AC    TH Clinical investigators Practicing oncologists 2% 0% Disagree 10% 0% In between 100% 88% Agree
If yes, please respond to the following statements about the BCIRG 006 study:  The TOPO II test is useful to determine whether an anthracycline should be used in the HER2-positive setting Clinical investigators Practicing oncologists 26% 70% Disagree 43% 24% In between 6% 31% Agree
Have you ever ordered a TOPO II test? 8.6 4.3 If yes, how many times? (mean) 14% 5% Percent answering yes Clinical investigators Practicing oncologists
Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative, node-negative  tumor in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy? 82% 73% Percent answering yes Clinical investigators Practicing oncologists
Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative  tumor with  3 positive nodes in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy? 69% 53% Percent answering yes Clinical investigators Practicing oncologists

More Related Content

What's hot

Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121lefein
 
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!National Ovarian Cancer Coalition
 
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitment
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitmentPI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitment
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitmentLiana Castel, PhD, MSPH, BA
 
cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?Kanhu Charan
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelinesfondas vakalis
 
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerbreastcancerupdatecongress
 
Metformin and cancer journal club
Metformin and cancer  journal clubMetformin and cancer  journal club
Metformin and cancer journal clubmadurai
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERAaditya Prakash
 
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Dana-Farber Cancer Institute
 
Discuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryDiscuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryAbdullahi Sanusi
 
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-AymanNeoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Aymansurgizag
 
Post neoadjuent breast cancer tumor size
Post neoadjuent breast cancer tumor size Post neoadjuent breast cancer tumor size
Post neoadjuent breast cancer tumor size imrana tanvir
 
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.imrana tanvir
 

What's hot (20)

Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121
 
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
Immunotherapy and Recurrent Ovarian Cancer: Time for New Paradigms!
 
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitment
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitmentPI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitment
PI-to-Oncologists briefing for clinical study (NCT00954564) patient recruitment
 
Locally advanced breast cancer
Locally advanced breast cancerLocally advanced breast cancer
Locally advanced breast cancer
 
What’s New With HER2?
What’s New With HER2?What’s New With HER2?
What’s New With HER2?
 
cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?cCR TO NACTRT RECTUM-WHAT NEXT?
cCR TO NACTRT RECTUM-WHAT NEXT?
 
Understanding Breast Cancer Guidelines
Understanding Breast Cancer GuidelinesUnderstanding Breast Cancer Guidelines
Understanding Breast Cancer Guidelines
 
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancerNoa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
Noa Efrat Ben Baruch : Neo-adjuvant treatment in breast cancer
 
Imaging After Breast Cancer
Imaging After Breast CancerImaging After Breast Cancer
Imaging After Breast Cancer
 
Metformin and cancer journal club
Metformin and cancer  journal clubMetformin and cancer  journal club
Metformin and cancer journal club
 
LANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCERLANDMARK TRIALS IN BREAST CANCER
LANDMARK TRIALS IN BREAST CANCER
 
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
Moving Beyond Resistance: Current Research in ER+ Metastatic Breast Cancer
 
2.1 adj cht cufer
2.1 adj cht cufer2.1 adj cht cufer
2.1 adj cht cufer
 
Discuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgeryDiscuss the principles guiding the use of radiotherapy in surgery
Discuss the principles guiding the use of radiotherapy in surgery
 
NCCN Guidelines for Patients: Ovarian Cancer
NCCN Guidelines for Patients: Ovarian CancerNCCN Guidelines for Patients: Ovarian Cancer
NCCN Guidelines for Patients: Ovarian Cancer
 
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-AymanNeoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
Neoadjuvant and hormonal therapy in Breast cancer - Yousef El-Ayman
 
Post neoadjuent breast cancer tumor size
Post neoadjuent breast cancer tumor size Post neoadjuent breast cancer tumor size
Post neoadjuent breast cancer tumor size
 
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
Pathological assesment of carcinoma breast after neoadjuvant chenotherapy.
 
SENTINA Trial
SENTINA TrialSENTINA Trial
SENTINA Trial
 
Fifth Annual Metastatic Breast Cancer Forum
Fifth Annual Metastatic Breast Cancer ForumFifth Annual Metastatic Breast Cancer Forum
Fifth Annual Metastatic Breast Cancer Forum
 

Viewers also liked

MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...European School of Oncology
 
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatment
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatmentMCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatment
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatmentEuropean School of Oncology
 
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.Osama Elzaafarany, MD.
 
Advanced&metastatic breast cancer
Advanced&metastatic breast cancerAdvanced&metastatic breast cancer
Advanced&metastatic breast cancerMahran Alnahmi
 
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerAdjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerNazia Ashraf
 
Breast Cancer Trials And Tribulations Revised Oct 09
Breast Cancer Trials And Tribulations Revised Oct 09Breast Cancer Trials And Tribulations Revised Oct 09
Breast Cancer Trials And Tribulations Revised Oct 09fondas vakalis
 

Viewers also liked (6)

MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
MCO 2011 - Slide 8 - E. Senkus-Konefka - Treatment of metastatic disease and ...
 
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatment
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatmentMCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatment
MCO 2011 - Slide 7 - A. Goldhirsch - Early systemic treatment
 
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.
Adding Trastuzumab to Adjuvant Chemotherapy in Breast Cancer.
 
Advanced&metastatic breast cancer
Advanced&metastatic breast cancerAdvanced&metastatic breast cancer
Advanced&metastatic breast cancer
 
Adjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancerAdjuvant treatment in early and localy advanced breast cancer
Adjuvant treatment in early and localy advanced breast cancer
 
Breast Cancer Trials And Tribulations Revised Oct 09
Breast Cancer Trials And Tribulations Revised Oct 09Breast Cancer Trials And Tribulations Revised Oct 09
Breast Cancer Trials And Tribulations Revised Oct 09
 

Similar to POC Breast 1 | 2007 - Adjuvant Trastuzumab

Adjuvant chemotherapy of breast cancer
Adjuvant chemotherapy of breast cancerAdjuvant chemotherapy of breast cancer
Adjuvant chemotherapy of breast cancerGita Bhat
 
Breast Cancer Awareness
Breast Cancer AwarenessBreast Cancer Awareness
Breast Cancer AwarenessQueens Library
 
Breast landmark trials dr.kiran
Breast landmark trials dr.kiranBreast landmark trials dr.kiran
Breast landmark trials dr.kiranKiran Ramakrishna
 
management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022Dr. Naina Kumar Agarwal
 
Metastatic breast cancer
Metastatic breast cancerMetastatic breast cancer
Metastatic breast cancerJyoti Sharma
 
Advances In Adjuvant Systemic Therapy Of Breast Cancer
Advances In Adjuvant Systemic Therapy Of Breast CancerAdvances In Adjuvant Systemic Therapy Of Breast Cancer
Advances In Adjuvant Systemic Therapy Of Breast Cancerfondas vakalis
 
ADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxnann22
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDKamelFarag4
 
Her2 ebc webinar
Her2 ebc webinarHer2 ebc webinar
Her2 ebc webinarmadurai
 
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptxdrjuanpablooncologo
 
Treatment Deintensification in HPV positive head and neck cancer
Treatment Deintensification in HPV positive head and neck cancerTreatment Deintensification in HPV positive head and neck cancer
Treatment Deintensification in HPV positive head and neck cancerDr Rushi Panchal
 
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...Diaa A. Hameed
 
Systemic Therapy in Breast Cancer.pptx
Systemic Therapy in Breast Cancer.pptxSystemic Therapy in Breast Cancer.pptx
Systemic Therapy in Breast Cancer.pptxAtulGupta369
 
EBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptxEBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptxJerubAlex1
 
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...bkling
 

Similar to POC Breast 1 | 2007 - Adjuvant Trastuzumab (20)

Adjuvant chemotherapy of breast cancer
Adjuvant chemotherapy of breast cancerAdjuvant chemotherapy of breast cancer
Adjuvant chemotherapy of breast cancer
 
Breast Cancer Awareness
Breast Cancer AwarenessBreast Cancer Awareness
Breast Cancer Awareness
 
Breast landmark trials dr.kiran
Breast landmark trials dr.kiranBreast landmark trials dr.kiran
Breast landmark trials dr.kiran
 
Katherine trial
Katherine trialKatherine trial
Katherine trial
 
management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022management of locally advanced breast cancer 2022
management of locally advanced breast cancer 2022
 
Metastatic breast cancer
Metastatic breast cancerMetastatic breast cancer
Metastatic breast cancer
 
Advances In Adjuvant Systemic Therapy Of Breast Cancer
Advances In Adjuvant Systemic Therapy Of Breast CancerAdvances In Adjuvant Systemic Therapy Of Breast Cancer
Advances In Adjuvant Systemic Therapy Of Breast Cancer
 
ADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptxADC-Overview-and-Application.v7.20201117.pptx
ADC-Overview-and-Application.v7.20201117.pptx
 
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MDBreast cancer oncotype-dx.. by dr.Kamel Farag, MD
Breast cancer oncotype-dx.. by dr.Kamel Farag, MD
 
Her2 ebc webinar
Her2 ebc webinarHer2 ebc webinar
Her2 ebc webinar
 
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx
12-Eric-Winer-winer-neoadjuvant-HER2_v02.pptx
 
Treatment Deintensification in HPV positive head and neck cancer
Treatment Deintensification in HPV positive head and neck cancerTreatment Deintensification in HPV positive head and neck cancer
Treatment Deintensification in HPV positive head and neck cancer
 
Tnbc 2018 update
Tnbc 2018 updateTnbc 2018 update
Tnbc 2018 update
 
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
The New Immuno-Oncology Era in Early-Stage Bladder Cancer: Readying the Moder...
 
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...Neoadjuvant Chemotherapy in muscle invasive bladder cancer:The Standard of ...
Neoadjuvant Chemotherapy in muscle invasive bladder cancer: The Standard of ...
 
Systemic Therapy in Breast Cancer.pptx
Systemic Therapy in Breast Cancer.pptxSystemic Therapy in Breast Cancer.pptx
Systemic Therapy in Breast Cancer.pptx
 
Neoadjuvant treatment for esophageal and gastric cancer
Neoadjuvant treatment for esophageal and gastric cancerNeoadjuvant treatment for esophageal and gastric cancer
Neoadjuvant treatment for esophageal and gastric cancer
 
Portec 4a
Portec 4aPortec 4a
Portec 4a
 
EBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptxEBC ROLE OF SYSTEMIC THERAPY.pptx
EBC ROLE OF SYSTEMIC THERAPY.pptx
 
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
SHARE Presentation: New Developments in the Medical Treatment of Breast Cance...
 

Recently uploaded

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 

Recently uploaded (20)

MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 

POC Breast 1 | 2007 - Adjuvant Trastuzumab

  • 1. Patterns of Care in Medical Oncology Adjuvant Trastuzumab
  • 2. Patients with HER2-positive, node-negative breast tumors 1-2 cm should generally receive adjuvant trastuzumab/chemotherapy as part of their treatment. 5% 0% Disagree 12% 24% In between 83% 76% Agree ER-positive ER-negative 0% 2% 98% 3% 8% 89% Disagree In between Agree Clinical investigators Practicing oncologists
  • 3. Patients with HER2-positive, node-negative breast tumors smaller than 1 cm should generally receive adjuvant trastuzumab/chemotherapy as part of their treatment. 33% 35% Disagree 40% 47% In between 27% 18% Agree ER-positive ER-negative 14% 49% 37% 15% 37% 48% Disagree In between Agree Clinical investigators Practicing oncologists
  • 4. When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy regimen do you generally use? 2007 2006 12% 2% Other 0% 2% AC  paclitaxel q3wk Clinical investigators (CI) 0% 20% 22% 46% 4% AC  docetaxel 2% 25% 65% Docetaxel/carboplatin Dose-dense AC  paclitaxel q2wk AC  paclitaxel qwk
  • 5. When using adjuvant trastuzumab for patients with breast cancer, which adjuvant chemotherapy regimen do you generally use? 2006 PO n = 143 2007 2006 9% 2% Other 13% 2% AC  paclitaxel q3wk Practicing oncologists (PO) 9% 8% 27% 34% 17% AC  docetaxel 4% 31% 44% Docetaxel/carboplatin Dose-dense AC  paclitaxel q2wk AC  paclitaxel qwk
  • 6. Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are unable to receive chemotherapy. 2007 2006 Clinical investigators (CI) 30% 35% 35% 38% 24% 38% Disagree In between Agree
  • 7. Trastuzumab monotherapy is a reasonable nonprotocol adjuvant treatment option for patients with breast cancer who are unable to receive chemotherapy. 2007 2006 Practicing oncologists (PO) 17% 33% 50% 27% 36% 37% Disagree In between Agree
  • 8. Approximately what percent of your patients on adjuvant trastuzumab fail to complete one year of trastuzumab therapy? 10% 13% Mean Clinical investigators Practicing oncologists
  • 9. Have you used TCH as nonprotocol adjuvant therapy for patients with HER2-positive tumors? 75% 44% Percent answering yes Clinical investigators Practicing oncologists
  • 10. For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/taxane/trastuzumab regimen? * CI n = 49, PO n = 147 1% 0% My preferred regimen is significantly more efficacious Efficacy* 33% 65% 2% 0% 30% My preferred regimen is somewhat more efficacious 54% 13% 2% Both are similar in efficacy TCH is somewhat more efficacious TCH is significantly more efficacious Clinical investigators Practicing oncologists
  • 11. For a woman in average health with a 1.2-cm, Grade II, ER-positive/PR-positive, HER2-positive tumor with 3 positive nodes, how would you compare TCH to your preferred anthracycline/taxane/trastuzumab regimen? † CI n = 49, PO n = 149 0% 2% My preferred regimen has significantly better safety and tolerability Safety and tolerability † 8% 37% 33% 20% 7% My preferred regimen has somewhat better safety and tolerability 28% 53% 12% Both are similar in safety and tolerability TCH has somewhat better safety and tolerability TCH has significantly better safety and tolerability Clinical investigators Practicing oncologists
  • 12. How would you feel in general about recommending participation in a randomized trial of TCH alone or with bevacizumab in women with HER2-positive breast cancer? 8% 6% I would not recommend participation 45% 41% Some concerns — I would enter patients selectively 53% 47% No concerns — I would enter patients Clinical investigators Practicing oncologists
  • 13. Are you aware of the new data from the BCIRG 006 study comparing AC   T to AC   TH and to TCH in the adjuvant treatment of HER2-positive, early breast cancer presented at the 2006 San Antonio Breast Cancer Symposium? AC  TH = doxorubicin/cyclophosphamide  docetaxel/trastuzumab; TCH = docetaxel/carboplatin/trastuzumab Clinical investigators Practicing oncologists 100% 68% Percent answering yes
  • 14. If yes, please respond to the following statements about the BCIRG 006 study: THC and AC   TH had roughly equivalent efficacy, and each was superior to AC   T 4% 0% Disagree 11% 10% In between 90% 85% Agree Clinical investigators Practicing oncologists
  • 15. If yes, please respond to the following statements about the BCIRG 006 study: TCH had lower cardiovascular toxicity compared to AC   TH Clinical investigators Practicing oncologists 2% 0% Disagree 10% 0% In between 100% 88% Agree
  • 16. If yes, please respond to the following statements about the BCIRG 006 study: The TOPO II test is useful to determine whether an anthracycline should be used in the HER2-positive setting Clinical investigators Practicing oncologists 26% 70% Disagree 43% 24% In between 6% 31% Agree
  • 17. Have you ever ordered a TOPO II test? 8.6 4.3 If yes, how many times? (mean) 14% 5% Percent answering yes Clinical investigators Practicing oncologists
  • 18. Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative, node-negative tumor in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy? 82% 73% Percent answering yes Clinical investigators Practicing oncologists
  • 19. Would you be comfortable enrolling a patient with a 1.2-cm, HER2-positive, ER-negative tumor with 3 positive nodes in a randomized clinical trial that has one arm containing lapatinib as the only anti-HER2 therapy? 69% 53% Percent answering yes Clinical investigators Practicing oncologists